How many stocks are there of Precigen?
The current number of stocks of Precigen is 244.54 M undefined.
Precigen Stocks 2024
Precigen Stocks
244.54 M
Ticker
PGEN
ISIN
US74017N1054
WKN
A2PZG1
In 2024, Precigen had 244.54 M outstanding stocks, a 0% change from the 244.54 M stocks in the previous year.
The Precigen Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 244.54 |
| 2028e | 244.54 |
| 2027e | 244.54 |
| 2026e | 244.54 |
| 2025e | 244.54 |
| 2024e | 244.54 |
| 2023 | 244.54 |
| 2022 | 200.4 |
| 2021 | 197.8 |
| 2020 | 167.1 |
| 2019 | 154.1 |
| 2018 | 129.5 |
| 2017 | 120 |
| 2016 | 118 |
| 2015 | 111.1 |
| 2014 | 99.2 |
| 2013 | 41 |
| 2012 | 5.5 |
| 2011 | 5.2 |
Precigen shares outstanding US74017N1054 · A2PZG1
The number of shares was Precigen in 2023 — This indicates how many shares 244.536 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Precigen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Precigen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Precigen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Precigen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 5.2 M Aktien |
| 2012 | 5.5 M Aktien |
| 2013 | 41 M Aktien |
| 2014 | 99.2 M Aktien |
| 2015 | 111.1 M Aktien |
| 2016 | 118 M Aktien |
| 2017 | 120 M Aktien |
| 2018 | 129.5 M Aktien |
| 2019 | 154.1 M Aktien |
| 2020 | 167.1 M Aktien |
| 2021 | 197.8 M Aktien |
| 2022 | 200.4 M Aktien |
| 2023 | 244.54 M Aktien |
| 2024e | 244.54 M Aktien |
| 2025e | 244.54 M Aktien |
| 2026e | 244.54 M Aktien |
| 2027e | 244.54 M Aktien |
| 2028e | 244.54 M Aktien |
| 2029e | 244.54 M Aktien |
Precigen Aktienanalyse
What does Precigen do?
Precigen Inc is a biotechnology company headquartered in Germantown, Maryland, USA. The company was founded in 1991 under the name Human Genome Sciences Inc and became the first company in the industry to unlock genetic genes for drug development. In 2019, the company was renamed Precigen Inc. The company specializes in the development of cell and gene therapy products based on the latest advances in regenerative medicine. The goal is to treat diseases that have been difficult or even considered incurable through gene therapy, genome sequencing, and artificial intelligence. Precigen is divided into several divisions: Precigen ActoBio, Precigen Genome, Precigen RegenX, and Precigen Triple Gem. The divisions differ in product development and target application areas. Precigen ActoBio focuses on the development of biological therapies for autoimmune diseases. The company is working on an oral immunotherapy that can treat respiratory and inflammatory bowel diseases. The product is in the testing phase and if all goes well, approval could be within reach. Precigen Genome specializes in genome sequencing. The data from the genes is decoded to develop better medical diagnoses and therapies. Precigen Genome's services range from sequencing genomic information to uncovering further details to interpreting genome data. Precigen RegenX develops gene therapy products for the treatment of rare but severe genetic diseases. The aim is to modify specific genes in the body to achieve a cure or alleviate symptoms. An example of a product from Precigen RegenX is a gene therapy for hemophilia. This product is being tested in phase II clinical trials and could represent a true revolution in treatment. Precigen Triple Gem is the company's newest division, founded in 2020. It is a research and development project focused on novel cancer therapies. The main focus is on the development of CAR-T cells that can recognize and destroy various types of cancer cells. The company has already achieved promising results. The products from Precigen aim to simplify the treatment of severe diseases and minimize side effects through integration into molecular medicine. Patient safety is the top priority. To ensure this, strict testing phases are undergone and there is close monitoring of product development. Precigen's business strategy is based on collaboration with other companies and institutions. The company works with large pharmaceutical companies to support production, distribution, and marketing of the products, among other partnerships. Another important partnership is with universities and research institutions, which help the company in developing new technologies, improving production processes, and conducting clinical trials. This collaboration leads to faster research insights and a larger pool of knowledge and know-how. Precigen is also committed to recruiting the best talent and qualified personnel in the field of biotechnology. Overall, Precigen is an extremely innovative and promising company in the field of regenerative medicine and gene therapy. The company relies on a clever business strategy and forward-thinking partnerships to develop even better therapies for serious, previously incurable diseases in the future. Precigen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Precigen's Shares Outstanding
Precigen's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Precigen’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Precigen’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Precigen’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Precigen stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Precigen are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Precigen evolved in recent years?
The number of shares of Precigen has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Precigen as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Precigen?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Precigen pay?
Over the past 12 months, Precigen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Precigen is expected to pay a dividend of 0 USD.
What is the dividend yield of Precigen?
The current dividend yield of Precigen is .
When does Precigen pay dividends?
Precigen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Precigen?
Precigen paid dividends every year for the past 0 years.
What is the dividend of Precigen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Precigen located?
Precigen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Precigen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Precigen from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
When did Precigen pay the last dividend?
The last dividend was paid out on 10/5/2024.
What was the dividend of Precigen in the year 2023?
In the year 2023, Precigen distributed 0 USD as dividends.
In which currency does Precigen pay out the dividend?
The dividends of Precigen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Precigen
Our stock analysis for Precigen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Precigen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
